Address
Email address
Phone number
https://carlova.eeAvaleht - Ensüümid ja laboriplastikUue põlvkonna kuvamisinstrument Odyssey® M 5µm resolutsioon, 18 erinevat kanalit ning >6 log dünaamiline ulatus LI-COR Biotechnology ROHKEM INFOT Uue põlvkonna kuvamisinstrument Odyssey® M 5µm resolutsioon, 18 erinevat kanalit ning >6 log dünaamiline ulatus LI-COR Biotechnology ROHKEM INFOT Uue põlvkonna kuvamisinstrument Odyssey® M ROHKEM INFOT Meie partnerid OÜ Carlova Consult on alates aastast 2000 biotehnoloogia- […]
Name
Geenikliinik OÜ
Registry code
14851055
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
18.11.2019 (4)
Financial year
01.01-31.12
Capital
2 500.00 €
Activity
63111 - Data processing, hosting and related activities
-
-
-
-
-
-
Not submitted
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| OSAÜHING CARLOVA CONSULT 10667403 | 100% - 2 500.00 EUR | - | - | Founder |
| Andres Metspalu 11.03.1951 (73) | - | Board member | Direct ownership |
| 2020 19.07.2021 | 2021 04.08.2022 | 2022 02.10.2023 | |
|---|---|---|---|
| Total Revenue | 1 995 € | 3 000 € | 3 000 € |
| Net profit (loss) for the period | 518 € | 103 € | -77 € |
| Profit Margin | 26% | 3% | -3% |
| Current Assets | 3 361 € | 3 464 € | 3 415 € |
| Fixed Assets | - | - | - |
| Total Assets | 3 361 € | 3 464 € | 3 415 € |
| Current Liabilities | 343 € | 343 € | 371 € |
| Non Current Liabilities | - | - | - |
| Total Liabilities | - | - | - |
| Share Capital | - | - | - |
| Equity | 3 018 € | 3 121 € | 3 044 € |
| Employees | 0 | 0 | 0 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | - | 305.85 € | 331.59 € | 1 |
| 2023 Q4 | - | 305.85 € | 331.59 € | 1 |
| 2023 Q3 | - | 305.85 € | 331.59 € | 1 |
| 2023 Q2 | - | 305.85 € | 331.59 € | 1 |
| 2023 Q1 | - | 305.85 € | 331.59 € | 1 |
| 2022 Q4 | - | 305.85 € | 331.59 € | 1 |
| 2022 Q3 | - | 305.85 € | 331.59 € | 1 |
| 2022 Q2 | - | 290.15 € | 314.57 € | 1 |
| 2022 Q1 | - | 282.3 € | 306.06 € | 1 |
| 2021 Q4 | - | 282.3 € | 306.06 € | 1 |
| 2021 Q3 | - | 282.3 € | 306.06 € | 1 |
| 2021 Q2 | - | 282.3 € | 306.06 € | 1 |
| 2021 Q1 | - | 282.3 € | 306.06 € | 1 |
| 2020 Q4 | - | 282.3 € | 306.06 € | 1 |
| 2020 Q3 | - | 94.1 € | 102.02 € | 1 |
